Financial statements Biosenseis
Company suspended its operations from 2024-07-05
Balance sheet data of BIOSENSEIS
|
Year
|
2020
|
2022
|
2023
|
|---|---|---|---|
| Total assets | 746 693,41 | 879 854,56 | 944 930,79 |
| A. Fixed assets | 151 528,77 | 0,00 | 0,00 |
| B. Current assets | 595 164,64 | 879 854,56 | 944 930,79 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 |
| Total liabilities | 746 693,41 | 879 854,56 | 944 930,79 |
| A. Equity | 413 548,50 | 422 234,00 | 486 250,93 |
| B. Liabilities and provisions for liabilities | 333 144,91 | 457 620,56 | 458 679,86 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 |
| II. Short-term liabilities | 333 144,91 | 457 620,56 | 458 679,86 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.